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Background: The risk of recurrence after resection of non-metastatic gastro-entero-
pancreatic neuroendocrine tumors (GEP-NET) is poorly defined. We developed/
validated a nomogram to predict risk of recurrence after curative-intent resection.
Methods: A training set to develop the nomogram and test set for validation were
identified. The predictive ability of the nomogram was assessed using c-indices.
Results: Among 1477 patients, 673 (46%) were included in the training set and 804
(54%) in the y test set. On multivariable analysis, Ki-67, tumor size, nodal status, and
invasion of adjacent organs were independent predictors of DFS. The risk of death
increased by 8% for each percentage increase in the Ki-67 index (HR 1.08, 95% CI,
1.05-1.10; P < 0.001). GEP-NET invading adjacent organs had a HR of 1.65 (95% CI,
1.03-2.65; P = 0.038), similar to tumors ≥3 cm (HR 1.67, 95%CI, 1.11-2.51; P = 0.014).
Patients with 1-3 positive nodes and patients with >3 positive nodes had a HR of 1.81
(95% CI, 1.12-2.87; P = 0.014) and 2.51 (95% CI, 1.50-4.24; P < 0.001), respectively.
The nomogram demonstrated good ability to predict risk of recurrence (c-index:
training set, 0.739; test set, 0.718).
Conclusion: The nomogramwas able to predict the risk of recurrence and can be easily
applied in the clinical setting.
K E YWORD S
neuroendocrine tumors, nomogram, recurrence
Katiuscha Merath and Fabio Bagante equally contributed to this manuscript.
868 | © 2018 Wiley Periodicals, Inc. wileyonlinelibrary.com/journal/jso J Surg Oncol. 2018;117:868–878.
Correspondence
Timothy M. Pawlik, MD, MPH, PhD, FACS,
Department of Surgery, The Urban Meyer III
and Shelley Meyer Chair in Cancer Research,
The Ohio State University Wexner Medical




Gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) are a
heterogeneous group of tumors that originate from the diffuse
neuroendocrine cell system of the gastrointestinal tract and
pancreas.1 Even though GEP-NET have classically been considered
rare neoplasia, recent data have suggested an exponential increase
in the incidence of GEP-NET over the last several decades.2–5
Specifically, the annual age-adjusted incidence of GEP-NET was 1.09
per 100 000 persons in 1973 compared with 6.98 per 100 000
persons in 2012—a sixfold increase.4 The prevalence of GEP-NET is
now higher than all other gastrointestinal cancers except for
colorectal neoplasia.3 GEP-NET tumors can present with a wide
range of histologic features and clinical presentations, as well as
variable biological behavior. Depending on the primary site and
grade, GEP-NET can have an indolent or aggressive course that can
be resistant to many types of treatment.6 For patients with loco-
regional disease, curative-intent surgical management of the primary
tumor is first-line treatment. In contrast, for patients with more
advanced metastatic disease, the goals of resection may include both
symptom control, debulking to limit tumor progression, as well as
attempts at complete surgical extirpation.7
While data on overall survival has more commonly been
reported, the risk of recurrence following curative resection of
primary NET has been less defined. Specifically, data on recurrence
after resection, including incidence of recurrence, recurrence pattern
and prognostic factors associated with recurrence, remain relatively
scarce.4,8–11 Data on recurrence is, however, important to inform
patients about the likelihood of treatment success and the risk of
recurrence following surgical intervention. In particular, accurate
individual patient-based estimates of risk of recurrence may not only
assist with patient counseling and inform decision-making, but also
help guide follow-up. While nomograms have been reported as
useful tools to discriminate the prognosis of patients for a number of
different cancers, nomograms have not been widely applied to
patients with GEP-NET.12 Therefore, the objective of the current
study was to identify factors associated with recurrence among
patients who underwent curative intent resection of GEP-NET using
a large multi-institutional database. Using these factors, we sought
to develop and validate a nomogram to predict individual patient-
specific risk of recurrence after curative-intent surgical resection of
non-metastatic primary GEP-NET.
2 | PATIENTS AND METHODS
2.1 | Study population and data collection
In this retrospective cohort study, a multi-institutional database was
queried to identify patients who underwent surgery for histologically
confirmed GEP-NET between 2000 and 2014 at one of the eight
centers participating of the US Neuroendocrine Tumor Study Group
(US-NETSG). US-NETSG included The Ohio State University Wexner
Medical Center and James Comprehensive Cancer Center, Columbus,
OH;Winship Cancer Institute, Emory University, Atlanta, GA; Stanford
University, Palo Alto, CA; VirginiaMasonMedical Center, Seattle,WA;
University of Wisconsin, School of Medicine and Public Health,
Madison, WI; Washington University, School of Medicine, St. Louis,
MO; Vanderbilt University, Nashville, TN; University of Michigan, Ann
Arbor, MI. The Institutional Review Board of the participating
institutions approved the study. Only patients who underwent
curative-intent surgery for primary GEP-NET without metastasis
(M0) were included. Patients who underwent only non-surgical
treatments (percutaneous ablation or intra-arterial therapy), debulking,
and palliation were excluded. Standard patient demographic and
clinico-pathologic characteristics were collected, including age,
gender, American Society of Anesthesiologist (ASA) class of risk,
number of GEP-NET lesions, tumor size, invasion of adjacent organs,
margin status, tumor grade, Ki-67 index, and lymph node status.
2.2 | Statistical analysis
Discrete variables were described as medians with interquartile range
(IQR) and categorical variables were recorded as totals and frequen-
cies. Imputation for missing data were performed using fully
conditional specification (FCS) implemented by the multivariate
imputation by chained equations (MICE) algorithm.13 Univariable
comparisons were assessed using the chi-squared test or fisher's exact
test as appropriate. The outcome for survival analyses was disease-
free survival (DFS), defined as the time interval between the date of
surgery and the date of recurrence. Time was censored at the date of
the last follow-up assessment for patientswithout recurrence. Survival
curves were estimated using the Kaplan-Meier method and differ-
ences between the curves were compared using the log-rank test.
Variables that had a P-value <0.1 on univariate analyses were included
in the final multivariable model.
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A pseudo-randomization based on the day of birth was used to
identify a training set (patients born within the first 16 days of the
month of birth) to develop the model and a test set (patients born
within the last 15 days of the month of birth) to validate the model.14
Multivariable Cox proportional hazards models were used to evaluate
associations between variables and DFS. A sensitivity analysis was
performed on the un-imputed data to confirm the results of the
multivariable analysis. Continuous variables were included in the
nomogram using their original format or as categorical variables based
on clinical considerations and comparison of the performance of the
models with the continuous and categorical forms of the variables. The
final multivariable model was used to develop the nomogram.
Coefficients from the Cox models were reported as hazard ratios
(HR) with corresponding 95% confidence intervals (CI). A P-value of
<0.05 (two-tailed) was considered statistically significant. All analyses
were performed using STATA version 12.0 (StataCorp LP, College
Station, TX) and R software for statistical computing, v. 3.0.2 34, with
the additional packages: survival, mice, and Hmisc.13
3 | RESULTS
3.1 | Baseline characteristics
Table 1 lists the baseline characteristics of the 1477 patients in the
cohort. There were 723 (48.9%) men and 754 (51.1%) womenwith the
majority of patients being under the age of 65 years (n = 1039, 70.4%).
Most patients were ASA class 2 (n = 568, 41.3%) or 3 (n = 714, 52%),
while a smaller subset were class 1 (n = 65, 4.7%) or 4 (n = 27, 2%).
While GEP-NET was not associated with a genetic syndrome in the
overwhelming majority of patients (n = 1358, 91.9%), 72 (5%) and 11
(0.8%) patients were diagnosed with Multiple Endocrine Neoplasia
type 1 (MEN 1) and Von Hippel-Lindau (VHL) syndromes, respectively.
Overall, 880 (60.4%) patients had a functional GEP-NET. The primary
tumor site was pancreas in over one-half of cases (n = 948, 64.2%),
followed by jejunum-ileum (n = 198, 13.4%) or duodenum (n = 101,
6.8%). Other sites such as the stomach, appendix, rectum, colon,
ampulla, liver, and gallbladder were less common (n = 230, 15.6%).
On final pathology, primary tumor size was <3 cm in 1031 (69.8%)
patients. The vast majority of tumors were well differentiated
(n = 1101; 88.3%); 118 (9.5%) tumors were moderately differentiated
tumor, while 2.2% (n = 28) were poorly differentiated. Median Ki-67
index was 2% (IQR 1-5). Most patients had no lymph node metastasis
(n = 704, 60.7%); 317 (27.3%) patients had 1-3 lymph node metastasis
and 139 (12.0%) had >3 nodal metastasis. Perivascular and perineural
invasion were present in 36.2% (n = 387) and 25.3% (n = 25.3) of
tumors, respectively. Margin status was microscopically negative in
1246 (84.9%) patients.
3.2 | Factors associated with disease-free survival
The analytic cohort was divided into a training set (n = 754, 51.1%)
used to identify factors associatedwithDFS to develop the nomogram;
subsequently, 723 (48.9%) patients were included in the test set to
validate the nomogram. The baseline characteristics of patients
included in the training and test sets are reported in Table 1. Of
note, there were no differences in the clinico-pathologic variables in
the training versus test cohorts.
In assessing the 754 patients in the training cohort, several factors
were associatedwithDFS on univariable analysis (Table 2). Specifically,
patients with a <3% Ki-67 index had a 5-year DFS of 82.6% (95% CI,
71.05-89.7), while patients with tumors that had a 3-20% and >20%
Ki-67 index had 5-year DFS of 69.7% (95% CI, 57.8-78.9) and 26.6%
(95% CI, 7.3-51.1), respectively (P < 0.001). In addition, 5-year DFS
was 38.6% (95% CI, 13.4-63.6) among patients with poorly
differentiated GEP-NET, versus 65.2% (95% CI, 44.2-79.9) and
83.4% (95% CI, 78.6 −87.2) for patients with moderately and well-
differentiated tumors, respectively (P < 0.001). Tumor size was also
associated with long-term outcomes. Specifically, patients with GEP-
NET <3 cm had a 5-year DFS of 87.3% (95% CI, 82.5-90.8) versus
66.3% (95% CI, 57.8-73.5) for tumors ≥3 cm (P < 0.001). In addition, 5-
year DFS for patients with no lymph node metastasis was 84.6% (95%
CI, 79.2-87.1) compared with 71.8% (95% CI, 64.7-78.2) for patients
with 1-3 metastatic lymph nodes and 56.9% (95% CI, 46.1-69.5) for
patients with >3 metastatic lymph nodes (P < 0.001). On multivariable
analysis, Ki-67, tumor size, nodal status, and invasion of adjacent
organs remained independentpredictors associatedwithDFS (Table3).
Of note, the risk of death increased by 8% for each percentage increase
in the Ki-67 index (HR 1.08, 95% CI, 1.05-1.10; P < 0.001). Patients
with GEP-NET invading adjacent organs had a HR of 1.65 (95% CI,
1.03-2.65; P = 0.038), which was similar to the increased hazard of
death associatedwith tumor ≥3 cm in size (HR 1.67, 95%CI, 1.11-2.51;
P = 0.014). Furthermore, compared with patients who did not have
nodal metastasis, patients who had 1-3 positive nodes had 1.8-fold
increased risk of death (HR 1.81, 95% CI, 1.12-2.87; P = 0.014), while
patientswith >3 lymph nodemetastasis had a 2.5-fold increased risk of
death (HR 2.51, 95% CI, 1.50-4.24; P < 0.001). A sensitivity analysis
was performed on the un-imputed data, which confirmed the results of
the initial multivariable analysis. Subsequently, the beta-coefficients
from the final multivariable model were utilized to develop a
nomogram (Figure 1).
3.3 | Prediction ability of the nomogram and external
validation
The nomogram demonstrated a good ability to predict risk of
recurrence in both the training set (c-index 0.739; standard error
[se], 0.02) and the test set (c-index of 0.718; se, 0.03) (Supplemental
Figure S1). When the performance of the nomogram was tested in the
subgroups of patients characterized by different embryological origins
of primary GEP-NET (foregut, midgut, and hindgut), the ability of the
nomogram to predict the risk of recurrence was the same in all three
groups (P > 0.1). Particularly, the c-index was 0.767 (se, 0.03), 0.741
(se, 0.06), and 0.70 (se, 0.12) in the foregut, midgut, and hindgut
groups, respectively. In addition, while the Ki-67 index was included in
the model as a continuous variable, lymph node status and tumor size
were included as categorical variables. Subsequent analyses compared
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TABLE 1 Baseline characteristics of the cohort (N = 1477)
Variables N (%) Training set Test set P-value
All patients 1477 (100%) 754 (51.1%) 723 (48.9%) –
Age 0.98
<65 years 1039 (70.4%) 528 (70.4%) 508 (70.5%)
≥65 years 438 (29.6%) 226 (29.6%) 215 (29.5)
Gender 0.54
Male 723 (48.9%) 375 (49.7%) 348 (48.1%)
Female 754 (51.1%) 379 (50.3%) 375 (51.9%)
ASA class 0.89
1 65 (4.7%) 35 (4.9%) 30 (4.6%)
2 568 (41.3%) 296 (41.2%) 272 (41.5%)
3 714 (52.0%) 372 (51.7%) 342 (52.2%)
4 27 (2.0%) 16 (2.2%) 11 (1.7%)
NAa 103 35 68
Functional status 0.33
Non-functional 576 (39.6%) 305 (40.8%) 271 (38.3%)
Functional 880 (60.4%) 443 (59.2%) 437 (61.7%)
NAa 21 6 15
Genetic syndrome 0.91
Not syndromic 1358 (91.9%) 695 (93.6%) 663 (94.1%)
MEN 1 72 (5.0%) 38 (5.1%) 34 (4.8%)
VHL 11 (0.7%) 7 (0.9%) 4 (0.6%)
Neurofibromatosis 5 (0.3%) 2 (0.3%) 3 (0.4%)
Tuberous Sclerosis 2 (0.1%) 1 (0.1%) 1 (0.1%)
NAa 29 11 18
Multifocal 0.95
No 1222 (93.6%) 615 (93.6%) 607 (93.5%)
Yes 84 (6.4%) 42 (6.4%) 42 (6.5%)
NAa 171 97 74
Primary 0.75
Ampulla 28 (1.9%) 16 (2.1%) 12 (1.7%)
Appendix 48 (3.3%) 19 (2.5%) 29 (4.0%)
Colon 34 (2.3%) 14 (1.9%) 20 (2.8%)
Duodenum 101 (6.8%) 53 (7.0%) 48 (6.6%)
Gallbladder 4 (0.3%) 1 (0.1%) 3 (0.4%)
Liver 12 (0.8%) 8 (1.1%) 4 (0.6%)
Pancreas 948 (64.2%) 489 (64.9%) 459 (63.5%)
Rectum 37 (2.5%) 23 (3.1%) 14 (1.9%)
Small Bowel 198 (13.4%) 101 (13.4%) 97 (13.4%)
Stomach 67 (4.5%) 29 (3.9%) 38 (5.1%)
Tumor differentiation 0.79
Well differentiated 1101 (88.3%) 562 (88.2%) 539 (88.4%)
Moderately differentiated 118 (9.5%) 59 (9.3%) 59 (9.7%)
Poorly differentiated 28 (2.2%) 16 (2.5%) 12 (1.9%)
NAa 230 117 113
(Continues)
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the performances of the models including either continuous or
categorical forms of the variables to assess the risk of bias. These
analyses demonstrated no difference in the ability to predict the risk of
recurrence among the different models (all P > 0.1).
Based on the risk of recurrence predicted by the nomogram
(PRisk), patient overall risk of recurrence categorized into four distinct
groups: group 1 (PRisk <20%), group 2 (PRisk 20-40%), group 3 (PRisk
40-80%), and group 4 (PRisk >80%). Among the 1477 patients
analyzed, more than two third of patients (n = 1052, 71.2%) were in
group 1 (PRisk <20%), while 295 (20.0%), 112 (7.6%), and 18 (1.2%)
patients were in groups 2 (PRisk 20-40%), 3 (PRisk 40-80%), and 4
(PRisk >80%), respectively. Five-year DFS was 88.7% (95% IC, 85.7-
91.2), 68.4% (95% IC, 60.8-74.9), and 45.3% (95% IC, 32.9-56.9) in
group 1 (PRisk <20%), group 2 (PRisk 20-40%), and group 3 (PRisk 40-
80%), respectively. Of note, all patients in group 4 (PRisk >80%) had
recurrence within 3 years following surgery (Figure 2).
Among the 207 (14%) patients who relapsed, 98 (47.6%) patients
had recurrence <18 months from surgery, 42 (20.4%) recurred within
18-36 months, while 66 (32.0%) had recurrence >36 months from
surgery. Patients in group 1 (PRisk <20%) and group 2 (PRisk 20-40%)
had a higher incidence of recurrence >36 months from surgery (group
1, n = 33, 41.3%; group 2, n = 25, 34.7%), compared with recurrences
within 18-36 months from surgery (group 1, n = 15, 18.8%; group 2,
n = 10, 13.9%). Interestingly, patients in groups 3 (PRisk 40-80%), and 4
(PRisk >80%) demonstrated a higher likelihood or recurrence <18
months from the time of surgery (Figure 3A). Particularly, the incidence
of recurrence <18months from the time of surgery was 48.9% (n = 22)
for patients in nomogram group 1 and 77.8% for patients in group 4.
Among the 207 (14%) patients who relapsed, 63 (31.0%) patients
had local recurrence, while 140 (69.0%) patients had a distant
recurrence. Of note, the nomogram groupings were also associated
with the pattern of recurrence. Specifically, patients in group 1 (n = 37,
46.8%) and group 2 (n = 17, 23.6%) were more likely to recur locally
compared with patients in group 3 (n = 7, 16.3%) and group 4 (n = 2,
22.2%) (P = 0.0001)(Figure 3B). In contrast, the incidence of distant
recurrence was only 11.9% (n = 5) among patients in group 1 (PRisk
<20%) versus 60.0% among patients in group 4 (PRisk >80%)
(P = 0.008; Figure 3C).
4 | DISCUSSION
Current recommendations for peri-operative management (ie,
analogues of somatostatin, neo-adjuvant, and adjuvant chemotherapy)
and post-operative surveillance of patients who undergo
TABLE 1 (Continued)
Variables N (%) Training set Test set P-value
Ki-67 index, median (IQR) 2.0% (1-5) 2.6% (1-5) 2.0% (1-5) 0.87
Lymphnodes status 0.79
Negative 704 (60.7%) 368 (61.7%) 336 (59.6%)
1-3 Positives 317 (27.3%) 156 (26.2%) 161 (28.5%)
>3 Positives 139 (12.0%) 72 (12.1%) 67 (11.9%)
NAa 317 158 159
Tumor size 0.55
<3 cm 1031 (69.8%) 521 (69.1%) 510 (70.5%)
≥3 cm 446 (30.2%) 233 (30.9%) 213 (29.5%)
Final margin status 0.23
Negative 1246 (84.9%) 644 (85.9%) 602 (83.7%)
Positive 222 (15.1%) 105 (14.1%) 117 (16.3%)
NAa 9 5 4
Perivascular invasion 0.09
Absent 683 (63.8%) 369 (66.3%) 314 (61.2%)
Present 387 (36.2%) 188 (33.7%) 199 (38.8%)
NAa 407 197 210
Perineural invasion 0.90
Absent 706 (74.7%) 366 (74.5%) 340 (74.9%)
Present 239 (25.3%) 125 (25.5%) 114 (25.1%)
NAa 532 263 269
NA, not available.
aMultiple imputation was used to address missing data.
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TABLE 2 Univariate analysis, 5-year disease-free survival
Variables N (%) 5-year DFS (%) 95% CI P-value
All patients 754 (51.1) –
Age 0.88
<65 years 528 (70.4) 79.6 74.4-83.9
≥65 years 222 (29.6) 80.8 71.9-87.1
Gender 0.64
Male 375 (49.7) 79.9 73.8-84.8
Female 379 (50.3) 78.9 73.4-84.9
ASA class 0.98
1-2 331 (46.0) 80.2 73.7-85.3
3-4 388 (54.0) 79.2 72.5-84.4
Functional status 0.007
Non-functional 305 (40.8) 87.6 81.9-91.6
Functional 443 (59.2) 73.7 67.2-79.2
Genetic syndrome 0.24
Not associated 695 (93.0) 61.1 35.9-78.9
Associated 52 (7.0) 67.2 58.6-74.4
Multifocal 0.68
No 615 (93.6) 79.9 75.3-83.8
Yes 42 (6.4) 76.6 45.8-91.3
Primary 0.93
Gastriontestinal 265 (35.2) 71.9 61.5-80.0
Pancreas 489 (64.8) 67.7 44.8-74.8
Tumor differentiation <0.001
Well differentiated 562 (88.2) 83.4 78.6-87.2
Moderately differentiated 59 (9.3) 65.2 44.2-79.9
Poorly differentiated 16 (2.5) 38.6 13.4-63.6
Ki-67 index label <0.001
<3% 282 (60.3) 82.6 71.5-89.7
3-20% 162 (34.6) 69.7 57.8-78.9
>20% 24 (5.1) 26.6 7.3-51.1
Lymph node status <0.001
Negative 368 (48.8) 84.6 79.2-87.1
1-3 Positives 156 (20.7) 71.8 64.7-78.2
>3 Positives 72 (9.5) 56.9 46.1-69.5
Tumor size <0.001
<3 cm 521 (69.1) 87.3 82.5-90-8
≥3 cm 233 (30.9) 66.3 57.8-73.5
Final margin status 0.08
Negative 644 (85.9) 80.8 76.2-84.7
Positive 105 (14.1) 73.9 59.4-83.9
Lymph-vascular invasion <0.001
Absent 369 (66.3) 89.4 84.0-93.1
Present 188 (33.7) 61.5 50.9-70.6
Perineural invasion <0.001
(Continues)
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curative-intent surgery of primary GEP-NET are largely based on
expert opinion and small retrospective studies focused on specific
subtypes of neuroendocrine tumors.7,15–19 Moreover, the optimal
prognostic classification (ie, nomogram and staging system) to stratify
risk of recurrence for GEP-NET patients has not been defined. The
American Joint Committee on Cancer (AJCC) TNM classification is one
of the most common staging systems used in the clinical setting, which
is based on classic pathological variables including tumor character-
istics (T), lymph node status (N), and presence of distant metastases
(M).20 In 2010, the World Health Organization (WHO) described the
mitotic count and Ki-67 index as important parameters to effectively
grade GEP-NET and included these two parameters in the WHO
staging system.21 Subsequently, the European Neuroendocrine Tumor
Society (ENETS) combined the TNM classification with a grading
system based on both mitotic count and Ki-67 index.15,22,23 Even
though the ENETS staging system has demonstrated to be superior to
the AJCC TNM classification, several other clinico-pathologic charac-
teristics have been proposed as additional variables impacting the
prognosis of GEP-NET patients, including gender, age at diagnosis, site
of primary tumor, grade of differentiation, and site of metastatic
disease.24–26 There is also no consensus on the optimal cut-off value
for Ki-67 index that should be used to stratify patients’ prognosis.27,28
Furthermore, these staging systems have exclusively focused on
stratifying patients with regards to overall survival, rather than risk of
recurrence. The aim of our study was to develop and validate a
nomogram to accurately predict individual risk of recurrence after
curative resection of GEP-NET. Nomograms can bemore accurate and
clinically applicable tools to predict outcomes in the context of cancer
than conventional staging systems.12 Even though several previous
nomograms have been proposed to predict prognosis, risk of lymph
TABLE 2 (Continued)
Variables N (%) 5-year DFS (%) 95% CI P-value
Absent 366 (74.5) 85.9 80.1-90.2
Present 125 (25.5) 62.1 48.4-73.1
FIGURE 1 Nomogram predicting the risk of recurrence at 3-, 5-, and 10-year after surgery
FIGURE 2 Kaplan Meier curves for disease-free survival stratified
on the base of the risk of recurrence predicted by our nomogram
(PRisk): group 1 (PRisk <20%), group 2 (PRisk 20-40%), group 3
(PRisk 40-80%), and group 4 (PRisk >80%)
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nodemetastasis, distantmetastasis, and overall survival after resection
of primary GEP-NET, to the best of our knowledge, no nomograms or
staging system predicting the risk of recurrence, independently of the
anatomical site of primary GEP-NET, have been proposed.11,29–35
Particularly, the impact of the organ site of primary GEP-NET on
patients prognosis has not been completely clarified.36 In the current
analysis, site of primary GEP-NET was not associated with the risk of
recurrence and the predictive ability of the nomogramwas no different
among subgroups of patients categorized by different embryological
origins of primaryGEP-NET (foregut, midgut, and hindgut). The current
nomogram is important, therefore, as we developed and validated it
using a large multi-institutional international database, including only
patients with primary, non-metastatic, GEP-NET.
Four variables (ie, Ki-67 index as a continue variable, node status,
tumor size, and invasion of adjacent organs) were strongly associated
with risk of recurrence on multivariable analysis and were included in
the proposed nomogram. Ki-67 index has been identified as an
important biological variable for patients with GEP-NET.22,29,30,37–39
Even though ENETs and WHO 2010 classifications defined three
prognostic groups based on Ki-67 index cut-off values of 3% and 20%,
we chose to include Ki-67 as a continuous variable in the nomogram,
since Ellison et al had previously noted that Ki-67 index had a linear
relationship with survival.29 While the updated WHO 2017 classifica-
tion for neuroendocrine tumors proposed new cut-off values, several
authors have suggested a modification of the cut-off values for the Ki-
67 index to better stratify patient prognosis.28,40–42 Roughly 60% of
patients in our cohort had a Ki-67 index <3%, 35% a Ki-67 index
3-20%, and 5% of patients a Ki-67 index >20%. The 5-year DFS was
82.6% for patients in the <3%Ki-67 group, 69.7% for patients with Ki-
67 3-20%, and only 26.6% in the >20% Ki-67 group. In the proposed
nomogram, Ki-67 index was, however, a stronger predictor of
recurrence as a continuous variable versus a categorical variable.
Interestingly, when Ki-67 index was considered a continue variable,
the risk of recurrence increased by 8% for each additional percentage
point of Ki-67.
FIGURE 3 Comparison of the incidence of recurrence among the four PRisk groups identified: (A) recurrence <18 months from surgery,
recurrence within 18-36 months from surgery, and recurrence >36 months from surgery; (B) local and distal recurrence; (C) local plus distal
recurrence and distant recurrence
TABLE 3 Multivariable survival analysis
Variables HR 95% CI P-value
Tumor size 0.014
<3 cm – –
≥3 cm 1.67 1.11-2.51
Lymph node status
Negative – – –
1-3 positive nodes 1.81 1.12-2.87 0.014
>3 positive nodes 2.51 1.50-4.24 0.001
Ki-67 1.08 1.05-1.10 <0.001
Invasion of adjacent organs 0.038
Absent – –
Present 1.65 1.03-2.65
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Tumor size was also a strong predictor of recurrence and was
included in the nomogram as a categorical variable. Specifically,
patients with tumors <3 cm had a 5-year DFS of 87% versus 66% for
patients with tumors ≥3 cm. In fact, tumor size ≥3 cm conferred over a
1.5-fold increased risk of recurrence. Previous studies have similarly
demonstrated that tumor size can impact prognosis of patients with
GEP-NET. For example, Mosquera et al reported that the risk of
metastasis increased by 39% for each 1 cm increase in tumor size.35 In
a separate study, Fang et al reported that patients with tumors 2-4 cm
and >4 cm had an increased hazard of death compared with patients
with tumors smaller than 2 cm.11 In addition, data from other studies
have correlated tumor sizewith the risk of lymph nodemetastasis.43–45
To this point, Sohn et al reported that tumor grade combined with
tumor size is an important predictive factor for lymph node metastasis
and could serve as a prognostic factor for survival outcomes.46
Collectively, the data strongly suggest that tumor size impacts
prognosis of patients with GEP-NET tumors.
Even though lymph node status has been reported as an important
predictor of survival among patients with GEP-NET, there are less data
on the impact of metastatic nodal disease on the risk of recurrence.
Analyzing clinico-pathologic factors associated with recurrence in 188
patients who underwent surgery for GEP-NET, Slatger et al reported
that lymph node involvement was an important independent risk
factor for recurrence (HR 2.61; 95%CI, 1.17-5.83).39 In a separate
study, Dieckhoff et al reported that lymph node ratio (LNR) was amore
precise method to predict outcome rather than simple lymph node
status.47 In this analysis, patients with a LNR >0.2 had a 5-year DFS of
46% versus 76% for patients with a LNR ≤0.2.47 Similarly, Martin et al
reported an increased risk of death of 1.5-, 2-, and 3-fold for patients
with LNR ≤0.2 (HR, 1.5), LNR 0.2-0.5 (HR, 2.0), and LNR >0.5 (HR, 3.1),
respectively, compared with patients without nodal metastasis.10 In
the current analysis, the number of metastatic nodes was also strongly
associated with the risk of recurrence on both univariable and
multivariable analyses. Particularly, patients with node negative
disease had a 5-year DFS of 85% versus 72% for patients with 1-3
nodal metastases and a DFS of 57% for patients with >3 nodal
metastases. In fact, on multivariable analysis, compared with
individuals who were node negative, patients with 1-3 and >3 nodal
metastases had a 1.8- and 2.5-fold increased risk of recurrence.
While prognostic factors associated with recurrence after
resection of GEP-NET have been reported in the literature, data
regarding patterns of recurrence are scarce.37,39,47–49 Using the
Surveillance, Epidemiology, and End Results (SEER) and Medicare
databases, Shen et al analyzed patterns of recurrence after surgical
resection among 2366 patients with non-metastatic NETs. While 16%
of patients developed metastatic disease within 5 years, only 1% of
patients developed metastases between 5 and 10 years after surgery.
Moreover, only 10% of patients with local disease had recurrence
compared with 31% of patients with GEP-NET that invaded adjacent
organs or had lymph node metastasis.50 In a separate study, Strosberg
et al reported that the incidence of recurrence peaked approximately
2 years after surgery.51 In the current study, the proposed nomogram
demonstrated good ability to predict 3-, 5-, and 10-year recurrence in
both the training and test set. In addition, the nomogram groupings
were associated with timing and patterns of recurrence. For example,
patients in nomogram groups 1 and 2 were more likely to experience
recurrence >36 months from surgery. In contrast, patients in
nomogram groups 3 and 4 had a much higher high incidence of
recurrence <18 months from surgery, with recurrence >36 months
from surgery being less common. In addition to time of recurrence, the
nomogram groupings were associated with the pattern of recurrence.
Specifically, while the majority of patients in nomogram group 1 had a
similar incidence of local (47%) versus distal recurrence (53%), patients
in nomogram groups 3 and 4 were much more likely to experience a
distant recurrence rather than a local recurrence. These data strongly
suggest that a nomogram based on biological (Ki67, nodal status), as
well as anatomical (tumor size, invasion of adjacent organs) factors can
help identify which individual patients are at highest risk of recurrence.
Several limitations should be considered when interpreting the
results. Given the retrospective design and the multicenter nature of
the study, selection bias was possible. While a pseudo-randomization
was used to create two cohorts of patients for the development and
validation of the nomogram, the nomogram will require further
external validation in a separate cohort of patients. In addition, the
study cohort included only patients who underwent surgery at one of
eight specific academic centers in the United States. Therefore, the
results from the current study may not be generalizable to non-
academic, community centers, or lower volume centers.
5 | CONCLUSION
A nomogram based on four variables (ie, Ki-67, tumor size, invasion
of adjacent organs, and lymph node status) was able to predict the
risk of recurrence after surgery for GEP-NET. The nomogram
groupings were also associated with different timing and patterns of
recurrence. The nomogram demonstrated a good ability to identify
patients at risk of recurrence (c-index: training set 0.739, test set
0.718) and can be easily applied in the clinical setting. While this
nomogram will need to be further validated, nomograms such as the
one proposed herein may be helpful clinical tools for providers to
inform patients about the risk of recurrence, as well as personalize
adjuvant treatment and surveillance strategies following surgery for
patients with primary GEP-NET.
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